更新于：2024-11-04
Cobamamide
腺苷钴胺
更新于：2024-11-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C72H100CoN18O17P |
InChIKeyDWKMERNBNCCNEZ-RQKYJTTQSA-M |
CAS号13870-90-1 |
关联
2
项与 腺苷钴胺 相关的临床试验The Role of Cobamamide Supplements in Malnourished Patients
A Randomized, Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of HL-009 Liposomal Gel in Adult Patients With Mild to Moderate Atopic Dermatitis
100 项与 腺苷钴胺 相关的临床结果
登录后查看更多信息
100 项与 腺苷钴胺 相关的转化医学
登录后查看更多信息
100 项与 腺苷钴胺 相关的专利（医药）
登录后查看更多信息
392
项与 腺苷钴胺 相关的文献（医药）2024-08-29JOURNAL OF PHYSICAL CHEMISTRY B
Structural Evolution of Photoexcited Methylcobalamin toward a CarH-like Metastable State: Evidence from Time-Resolved X-ray Absorption and X-ray Emission
Article
作者: Ardana-Lamas, Fernando ; Sofferman, Danielle L. ; Song, Sanghoon ; Sension, Roseanne J. ; Meadows, Joseph H. ; Miller, Nicholas A. ; Otte, Florian ; Alonso-Mori, Roberto ; van Driel, Tim B. ; Biednov, Mykola ; Jiang, Yifeng ; Kubarych, Kevin J. ; Deb, Aniruddha ; Lamb, Ryan M. ; Kaneshiro, April K. ; Michocki, Lindsay B. ; Chung, Taewon ; McClain, Taylor P. ; Lima, Frederico Alves ; Khakhulin, Dmitry ; Penner-Hahn, James E. ; Uemura, Yohei
CarH is a protein photoreceptor that uses a form of B12, adenosylcobalamin (AdoCbl), to sense light via formation of a metastable excited state. Aside from AdoCbl bound to CarH, methylcobalamin (MeCbl) is the only other example─to date─of photoexcited cobalamins forming metastable excited states with lifetimes of nanoseconds or longer. The UV-visible spectra of the excited states of MeCbl and AdoCbl bound to CarH are similar. We have used transient Co K-edge X-ray absorption and X-ray emission spectroscopies in conjunction with transient absorption spectroscopy in the UV-visible region to characterize the excited states of MeCbl. These data show that the metastable excited state of MeCbl has a slightly expanded corrin ring and increased electron density on the cobalt, but only small changes in the axial bond lengths.
2024-08-02MEDICINE
Oculomotor nerve palsy caused by imidacloprid at initial diagnosis: A case report
Article
作者: Bu, Xiaoli ; Liu, Taixiang ; Jiang, Bing ; Jiang, Huan
Rationale::
Amid the pervasive deployment of imidacloprid, the incidence of poisoning from this compound has risen markedly. Those afflicted with imidacloprid poisoning typically exhibit symptoms ranging from headaches, dizziness, nausea, and abdominal pain, to impaired consciousness and breathlessness, yet instances of ocular paralysis induced by this toxin have not previously been documented.
Patient concerns::
When the pesticide spray inadvertently made contact with the patient’s eyes, they were seared with a burning sensation and discomfort. Subsequent to this incident, on the second day, the individual began to experience diplopia in the right eye and found it arduous to elevate his eyelids, indicating a challenge in achieving full extension.
Diagnoses::
Based on the medical history, symptoms, and signs, the patient was diagnosed with oculomotor nerve palsy caused by imidacloprid.
Interventions::
The treatment involved intravenous dexamethasone to reduce inflammatory response in the eye tissue; oral pantoprazole enteric-coated tablets to suppress acid production and protect the stomach; Xuesaitong administered intravenously to improve blood supply to the eye and promote metabolism of toxins; vitamin C, cobamamide, and vitamin B1 for nerve nutrition and antioxidant effects; local application of tobramycin-dexamethasone eye drops for anti-inflammatory purposes; and repeated flushing of the conjunctival sac with saline. Finally, the patient improved and was discharged.
Outcomes::
After active treatment, the patient finally improved diplopia and ptosis.
Lessons::
This report marks the first documentation of oculomotor nerve palsy induced by imidacloprid, featuring diplopia, and blepharoptosis without substantial limitation of ocular motility. Following therapeutic intervention, the patient showed marked improvement and was discharged from the hospital, providing a point of reference for the treatment of analogous cases in future clinical practice. It also serves as a reminder for the public to take appropriate precautions when using imidacloprid.
2024-02-16ACS synthetic biology
Standardized Iterative Genome Editing Method for Escherichia coli Based on CRISPR-Cas9
Article
作者: Zhang, Dawei ; Fang, Huan ; Dong, Ning ; Zhao, Xinfang ; Zhao, Ying ; Zhao, Jianghua
The introduction of complex biosynthetic pathways into the hosts' chromosomes is gaining attention with the development of synthetic biology. While CRISPR-Cas9 has been widely employed for gene knock-in, the process of multigene insertion remains cumbersome due to laborious and empirical gene cloning procedures. To address this, we devised a standardized iterative genome editing system for Escherichia coli, harnessing the power of CRISPR-Cas9 and MetClo assembly. This comprehensive toolkit comprises two fundamental elements based on the Golden Gate standard for modular assembly of sgRNA or CRISPR arrays and donor DNAs. We achieved a gene insertion efficiency of up to 100%, targeting a single locus. Expression of tracrRNA using a strong promoter enhances multiplex genomic insertion efficiency to 7.3%, compared with 0.76% when a native promoter is used. To demonstrate the robust capabilities of this genome editing toolbox, we successfully integrated 5-10 genes from the coenzyme B12 biosynthetic pathway ranging from 5.3 to 8 Kb in length into the chromosome of E. coli chassis cells, resulting in 14 antibiotic-free, plasmid-free producers. Following an extensive screening process involving genes from diverse sources, cistronic design modifications, and chromosome repositioning, we obtained a recombinant strain yielding 1.49 mg L-1 coenzyme B12, the highest known titer achieved by using E. coli as the producer. Illuminating its user-friendliness, this genome editing system is an exceedingly versatile tool for expediently integrating complex biosynthetic pathway genes into hosts' genomes, thus facilitating pathway optimization for chemical production.
100 项与 腺苷钴胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 营养紊乱 | 中国 | 1995-01-01 | |
| 恶性贫血 | 日本 | 1967-01-19 | |
| 关节痛 | 日本 | 1967-01-19 | |
| 中枢神经系统疾病 | 日本 | 1967-01-19 | |
| 面瘫 | 日本 | 1967-01-19 | |
| 白细胞减少 | 日本 | 1967-01-19 | |
| 吸收不良综合征 | 日本 | 1967-01-19 | |
| 肌痛 | 日本 | 1967-01-19 | |
| 神经痛 | 日本 | 1967-01-19 | |
| 神经炎 | 日本 | 1967-01-19 | |
| 绦虫病 | 日本 | 1967-01-19 | |
| 贫血 | - | - | - |
| 坐骨神经痛 | - | - | - |
| 三叉神经痛 | - | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 特应性皮炎 | 临床2期 | 美国 | 2012-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用